|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/05/24 Orthofix Medical Inc. 10-K 12/31/23 120:20M Donnelley … Solutions/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 4.65M
2: EX-10.16 Material Contract HTML 35K
3: EX-10.21 Material Contract HTML 36K
4: EX-21.1 Subsidiaries List HTML 44K
5: EX-23.1 Consent of Expert or Counsel HTML 39K
9: EX-97.1 Clawback Policy re: Recovery of Erroneously HTML 53K
Awarded Compensation
6: EX-31.1 Certification -- §302 - SOA'02 HTML 43K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 44K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 40K
11: R1 Document and Entity Information HTML 106K
12: R2 Consolidated Balance Sheets HTML 133K
13: R3 Consolidated Balance Sheets (Parenthetical) HTML 47K
14: R4 Consolidated Statements of Operations and HTML 128K
Comprehensive Loss
15: R5 Consolidated Statements of Changes in HTML 82K
Shareholders' Equity
16: R6 Consolidated Statements of Cash Flows HTML 154K
17: R7 Business and basis of presentation HTML 61K
18: R8 Significant accounting policies HTML 63K
19: R9 Recently adopted accounting standards and recently HTML 66K
issued accounting pronouncements
20: R10 Mergers and Acquisitions HTML 223K
21: R11 Inventories HTML 53K
22: R12 Property, plant and equipment HTML 82K
23: R13 Intangible assets HTML 111K
24: R14 Goodwill HTML 100K
25: R15 Leases HTML 190K
26: R16 Other current liabilities HTML 61K
27: R17 Indebtedness HTML 93K
28: R18 Fair value measurements and investments HTML 285K
29: R19 Commitments and contingencies HTML 50K
30: R20 Shareholder's equity HTML 96K
31: R21 Revenue recognition and accounts receivable HTML 113K
32: R22 Business segment information HTML 293K
33: R23 Acquisition-Related Amortization and Remeasurement HTML 67K
34: R24 Share-based compensation HTML 221K
35: R25 Defined Contribution Plans and deferred HTML 49K
compensation
36: R26 Income taxes HTML 291K
37: R27 Earnings per share (Eps) HTML 64K
38: R28 Significant accounting policies (Policies) HTML 157K
39: R29 Significant accounting policies (Tables) HTML 49K
40: R30 Mergers and Acquisitions (Tables) HTML 223K
41: R31 Inventories (Tables) HTML 53K
42: R32 Property, plant and equipment (Tables) HTML 77K
43: R33 Intangible assets (Tables) HTML 109K
44: R34 Goodwill (Tables) HTML 97K
45: R35 Leases (Tables) HTML 192K
46: R36 Other current liabilities (Tables) HTML 60K
47: R37 Indebtedness (Tables) HTML 71K
48: R38 Fair value measurements and investments (Tables) HTML 279K
49: R39 Shareholders' equity (Tables) HTML 90K
50: R40 Revenue recognition and accounts receivable HTML 90K
(Tables)
51: R41 Business segment information (Tables) HTML 289K
52: R42 Acquisition-Related Amortization and Remeasurement HTML 60K
(Tables)
53: R43 Share-based compensation (Tables) HTML 188K
54: R44 Income taxes (Tables) HTML 282K
55: R45 Earnings per share (Eps) (Tables) HTML 59K
56: R46 Significant Accounting Policies - Additional HTML 52K
Information (Detail)
57: R47 Significant accounting policies - Schedule of HTML 37K
Supplemental Disclosure of Cash Flow Information
(Detail)
58: R48 Recently Adopted Accounting Standards and Recently HTML 102K
Issued Accounting Pronouncements - Additional
Information (Detail)
59: R49 Mergers and acquisitions - Additional Information HTML 69K
(Detail)
60: R50 Mergers and acquisitions - Schedule of Estimated HTML 47K
Fair Value of Consideration Associated with Merger
(Detail)
61: R51 Mergers and acquisitions - Summary of Fair Values HTML 123K
of Assets Acquired and Liabilities Assumed
(Detail)
62: R52 Mergers and acquisitions - Summary of Pro Forma HTML 39K
Financial Information (Details)
63: R53 Mergers and acquisitions - Summary of Integration HTML 49K
Costs Incurred (Details)
64: R54 Mergers and acquisitions - Summary of HTML 61K
Restructuring Costs (Details)
65: R55 Inventories - Schedule of Inventories (Detail) HTML 44K
66: R56 Property, Plant and Equipment - Schedule of Useful HTML 52K
Lives of the Assets (Detail)
67: R57 Property, Plant and Equipment - Additional HTML 44K
Information (Detail)
68: R58 Property, Plant and Equipment - Schedule of HTML 58K
Property, Plant and Equipment (Detail)
69: R59 Intangible Assets - Schedule of Intangible Assets HTML 62K
(Detail)
70: R60 Intangible Assets - Additional Information HTML 37K
(Detail)
71: R61 Intangible Assets - Schedule of Future HTML 55K
Amortization Expense (Detail)
72: R62 Goodwill - Additional Information (Detail) HTML 47K
73: R63 Goodwill - Schedule of Net Carrying Amount of HTML 60K
Goodwill (Detail)
74: R64 Leases - Summary of Lease Portfolio (Detail) HTML 75K
75: R65 Leases - Summary of Components of Lease Costs HTML 49K
(Detail)
76: R66 Leases - Summary of Supplemental Cash Flow HTML 48K
Information Related to Leases (Detail)
77: R67 Leases - Summary of Remaining Lease Liabilities HTML 84K
(Detail)
78: R68 Other Current Liabilities - Summary of Other HTML 51K
Current Liabilities (Detail)
79: R69 Indebtedness - Summary of Carrying Values of HTML 60K
Outstanding Debt Obligations (Details)
80: R70 Indebtedness- Additional Information (Detail) HTML 117K
81: R71 Fair Value Measurements and Investments - Schedule HTML 63K
of Financial Assets and Liabilities Recorded at
Fair Value on Recurring Basis (Detail)
82: R72 Fair Value Measurements and Investments - HTML 51K
Additional Information (Detail)
83: R73 Fair Value Measurements and Investments - Schedule HTML 50K
of Reconciliation of Carrying Value of Investments
in Equity Securities (Detail)
84: R74 Fair Value Measurements and Investments - Schedule HTML 57K
of Reconciliation For Contingent Consideration
Measured At Fair Value Using Significant
Unobservable Inputs (Level 3) (Detail)
85: R75 Fair Value Measurements and Investments - Schedule HTML 62K
of Valuation Methodology and Unobservable Inputs
for Level 3 Assets and Liabilities Measured at
Fair Value (Detail)
86: R76 Fair Value Measurements and Investments - Schedule HTML 43K
of Change in Valuation of Securities (Detail)
87: R77 Commitments and Contingencies - Additional HTML 45K
Information (Detail)
88: R78 Shareholders' Equity - Components of Changes in HTML 60K
Accumulated Other Comprehensive Income (Loss)
(Detail)
89: R79 Revenue Recognition and Accounts Receivable - HTML 43K
Schedule of Net Sales (Detail)
90: R80 Revenue Recognition and Accounts Receivable - HTML 73K
Additional Information (Detail)
91: R81 Revenue Recognition and Accounts Receivable - HTML 47K
Schedule of Allowance for Expected Credit Losses
(Detail)
92: R82 Revenue Recognition and Accounts Receivable - HTML 38K
Schedule of Changes In Contract Liability (Detail)
93: R83 Business Segment Information - Additional HTML 36K
Information (Detail)
94: R84 Business Segment Information - Schedule of Net HTML 52K
Sales by Major Product Category by Reporting
Segment (Detail)
95: R85 Business Segment Information - Summary of EBIDTA HTML 75K
by Reporting Segment (Detail)
96: R86 Business Segment Information - Schedule of HTML 45K
Depreciation and Amortization by Reporting Segment
(Detail)
97: R87 Business Segment Information - Summary of Net HTML 54K
Sales by Geographic Destination for Each Reporting
Segment (Detail)
98: R88 Business Segment Information - Summary of Net HTML 55K
Sales by Geographic Destination (Detail)
99: R89 Business Segment Information - Summary of HTML 46K
Property, Plant and Equipment of Reporting
Segments by Geographic Area (Detail)
100: R90 Acquisition-Related Amortization and Remeasurement HTML 49K
- Components of Acquisition-Related Amortization
and Remeasurement (Detail)
101: R91 Acquisition-Related Amortization and Remeasurement HTML 50K
- Additional Information (Details)
102: R92 Share-based Compensation - Additional Information HTML 148K
(Detail)
103: R93 Share-based Compensation - Schedule of Share-Based HTML 56K
Compensation by Line Item in Consolidated
Statements of Income (Detail)
104: R94 Share-based Compensation - Schedule of Assumptions HTML 49K
Used in Determining Fair Value of Stock Options
Granted (Detail)
105: R95 Share-based Compensation - Schedule of Stock HTML 81K
Option Plans (Detail)
106: R96 Share-based Compensation - Schedule of Changes in HTML 82K
Time-Based and Market-Based Restricted Stock
Awards and Stock Units (Detail)
107: R97 Defined Contribution Plans and Deferred HTML 68K
Compensation - Additional Information (Detail)
108: R98 Income Taxes - Schedule of Income (Loss) Before HTML 44K
Provision for Income Taxes (Detail)
109: R99 Income Taxes - Schedule of Provision for Income HTML 55K
Taxes (Detail)
110: R100 Income Taxes - Schedule of Effective Income Tax HTML 95K
Rate Reconciliation for Continuing Operations
(Detail)
111: R101 Income Taxes - Additional Information (Detail) HTML 75K
112: R102 Income Taxes - Schedule of Deferred Tax Assets and HTML 86K
Liabilities (Detail)
113: R103 Income Taxes - Schedule of Gross Unrecognized Tax HTML 45K
Benefits (Excluding Interest and Penalties)
(Detail)
114: R104 Earnings Per Share (EPS) - Schedule of HTML 41K
Reconciliation of Weighted Average Shares Used in
the Diluted EPS (Detail)
115: R105 Earnings Per Share (EPS) - Additional Information HTML 40K
(Detail)
117: XML IDEA XML File -- Filing Summary XML 233K
120: XML XBRL Instance -- ofix-20231231_htm XML 5.25M
116: EXCEL IDEA Workbook of Financial Report Info XLSX 247K
10: EX-101.SCH XBRL Taxonomy Extension Schema With Embedded XSD 6.01M
Linkbases Document -- ofix-20231231
118: JSON XBRL Instance as JSON Data -- MetaLinks 769± 1.27M
119: ZIP XBRL Zipped Folder -- 0000950170-24-025877-xbrl Zip 780K
| EX-31.1 |
Exhibit 31.1
CERTIFICATION
I, Massimo Calafiore, certify that:
1. |
I have reviewed this annual report on Form 10-K of Orthofix Medical Inc.; |
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. |
The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
a. |
designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
b. |
designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
c. |
evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
d. |
disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has material affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. |
The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions): |
|
a. |
all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
|
b. |
any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
Dated: March 5, 2024 |
|
|
|
By: |
|
|
|
|
|
|
|
|
Name: Massimo Calafiore |
|
|
|
|
|
|
Title: President and Chief Executive Officer, Director |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/5/24 | 8-K | ||
| For Period end: | 12/31/23 | |||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 4/16/24 Orthofix Medical Inc. S-8 4/16/24 8:699K Donnelley … Solutions/FA 3/15/24 Orthofix Medical Inc. S-8 3/15/24 9:765K Donnelley … Solutions/FA |